Pharmacological cognitive enhancement from a perspective of misuse and addiction;Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin

Fortschritte der Neurologie Psychiatrie

Volumn 83, Issue 2, 2015, Pages 83-90

  Franke, A G ^a   Soyka, M ^b,c  

^a Hochschule Neubrandenburg   (Germany)

^b Privatklinik Meiringen ^*  (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

addiction; cognitive enhancement; misuse; stimulants; substance misuse addiction

Indexed keywords

ADDICTION; COGNITIVE ENHANCEMENT; DRUG MISUSE; HUMAN; PREVALENCE; REVIEW; SKILL; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

CENTRAL STIMULANT AGENT; NOOTROPIC AGENT;

CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NOOTROPIC AGENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84925386957     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0034-1398935     Document Type: Review

References (77)

1. World Anti-Doping Agency (WADA) Homepage of the WADA containing pdf file with prohibited substances. 2013; http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/ Accessed Nov. 2014
2. Forstl H. Neuro-enhancement. Brain doping. Nervenarzt: 2009; 80 840 846
3. Franke A. G., Lieb K. Pharmacological neuroenhancement and brain doping: Chances and risks. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz: 2010; 53 853 859
4. Simon P., Striegel H., Aust F. et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction: 2006; 101 1640 1644
5. Striegel H., Ulrich R., Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend: 2010; 106 230 232
6. Franke A. G., Lieb K. Pharmacological Neuroenhancement: Substances and Epidemiology. In: Hildt E., Franke A. G., Hrsg. Cognitive Enhancement - An Interdisciplinary Perspective. Heidelberg Springer Verlag: 2013; 17 27
7. Maher B. Poll results: look who's doping. Nature: 2008; 452 674 675
8. Soyka M. Neuro-enhancement from an addiction specialist's viewpoint. Nervenarzt: 2009; 80 837 839
9. Mehlman M. J. Cognition-enhancing drugs. Milbank Q: 2004; 82 483 506, table of contents
10. de Jongh R., Bolt I., Schermer M. et al. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev: 2008; 32 760 776
11. Middendorf E., Poskowsky J., Isserstedt W. Formen der Stresskompensation und Leistungssteigerung bei Studierenden. HISBUS-Befragung zur Verbreitung und zu Mustern von Hirndoping und Medikamentenmissbrauch. Hannover HIS Hochschul-Informations-System GmbH: 2012
12. Kramer P. D. Listening to Prozac. New York Viking Press: 1993
13. Normann C., Boldt J., Maio G. et al. Options, limits and ethics of pharmacological neuroenhancement. Nervenarzt: 2010; 81 66 74
14. Deutsche Angestelltenkrankenkasse (DAK) Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. Berlin/Hamburg DAK Forschung, IGES Institut GmbH: 2009
15. Franke A. G., Lieb K. Missbrauch von Psychopharmaka zum Cognitive Enhancement. InFo Neur Psych: 2009; 11 07 42 50
16. Arzneimittelfachinformation Coffeinum N 0,2g. Berlin MERCK dura: 2008
17. McLellan T. M., Lieberman H. R. Do energy drinks contain active components other than caffeine? Nutr Rev: 2012; 70 730 744
18. Giles G. E., Mahoney C. R., Brunye T. T. et al. Differential cognitive effects of energy drink ingredients: caffeine, taurine, and glucose. Pharmacol Biochem Behav: 2012; 102 569 577
19. Nehlig A., Daval J. L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev: 1992; 17 139 170
20. Fisone G., Borgkvist A., Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci: 2004; 61 857 872
21. Ferre S., Ciruela F., Borycz J. et al. Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci: 2008; 13 2391 2399
22. Lin F. J., Pierce M. M., Sehgal A. et al. Effect of taurine and caffeine on sleep-wake activity in Drosophila melanogaster. Nat Sci Sleep: 2010; 2 221 231
23. Ker K., Edwards P. J., Felix L. M. et al. Caffeine for the prevention of injuries and errors in shift workers. Cochrane Database Syst Rev: 2010; 10.1002/14651858.CD008508: CD008508
24. Foskett A., Ali A., Gant N. Caffeine enhances cognitive function and skill performance during simulated soccer activity. Int J Sport Nutr Exerc Metab: 2009; 19 410 423
25. Wesnes K. A., Barrett M. L., Udani J. K. An evaluation of the cognitive and mood effects of an energy shot over a 6h period in volunteers: a randomized, double-blind, placebo controlled, cross-over study. Appetite: 2013; 67 105 113
26. Ishak W. W., Ugochukwu C., Bagot K. et al. Energy drinks: psychological effects and impact on well-being and quality of life-a literature review. Innov Clin Neurosci: 2012; 9 25 34
27. Aggarwal R., Mishra A., Crochet P. et al. Effect of caffeine and taurine on simulated laparoscopy performed following sleep deprivation. Br J Surg: 2011; 98 1666 1672
28. Wesensten N. J. Legitimacy of concerns about caffeine and energy drink consumption. Nutr Rev: 2014; 72 01 78 86
29. Mariotti K. C., Rossato L. G., Froehlich P. E. et al. Amphetamine-type medicines: a review of pharmacokinetics, pharmacodynamics, and toxicological aspects. Curr Clin Pharmacol: 2013; 8 350 357
30. Repantis D., Schlattmann P., Laisney O. et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res: 2010; 62 187 206
31. Spencer R. C., Klein R. M., Berridge C. W. Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry: 2012; 72 221 227
32. Linssen A. M., Sambeth A., Vuurman E. F. et al. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Int J Neuropsychopharmacol: 2014; 17 961 977
33. Bagot K. S., Kaminer Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction: 2014; 109 547 557
34. Wood S., Sage J. R., Shuman T. et al. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev: 2014; 66 193 221
35. Minzenberg M. J., Carter C. S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology: 2008; 33 1477 1502
36. Sugden C., Housden C. R., Aggarwal R. et al. Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg: 2012; 255 222 227
37. Franke A. G., Heinrich I., Lieb K. et al. The use of Ginkgo biloba in healthy elderly. Age (Dordr): 2014; 36 435 444
38. Arzneimittelfachinformation Tebonin. Karlsruhe Schwabe: 2008
39. Diamond B. J., Bailey M. R. Ginkgo biloba: indications, mechanisms, and safety. Psychiatr Clin North Am: 2013; 36 73 83
40. Birks J., Grimley E. V., Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev: 2002; 10.1002/14651858.CD003120: CD003120
41. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev: 2007; 10.1002/14651858.CD003120.pub2: CD003120
42. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev: 2009; 10.1002/14651858.CD003120.pub3: CD003120
43. Tan M. S., Yu J. T., Tan C. C. et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis: 2015; 43 589 603
44. Solomon P. R., Adams F., Silver A. et al. Ginkgo for memory enhancement: a randomized controlled trial. JAMA: 2002; 288 835 840
45. Repantis D., Laisney O., Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res: 2010; 61 473 481
46. Yesavage J. A., Mumenthaler M. S., Taylor J. L. et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology: 2002; 59 123 125
47. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression∗ S3-Leitlinie/Nationale Versorgungs-Leitlinie Unipolare Depression - Kurzfassung, 1. Auflage 2009. Berlin, Düsseldorf DGPPN, ÄZQ, AWMF: 2009
48. Holsboer-Trachsler E., Holsboer F. Antidepressiva. In: Gründer G., Benkert O. Hrsg Handbuch der psychiatrischen Pharmakotherapie. Berlin Heidelberg Springer-Verlag: 2012; 589 628
49. Repantis D., Schlattmann P., Laisney O. et al. Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis Prax: 2009; 6 139 174
50. Wilens T. E., Adler L. A., Adams J. et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry: 2008; 47 21 31
51. Franke A. G., Bonertz C., Christmann M. et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry: 2011; 44 60 66
52. Franke A. G., Christmann M., Bonertz C. et al. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry: 2011; 44 331 338
53. Franke A. G., Lieb K., Hildt E. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS One: 2012; 7 e40047
54. Franke A. G., Schwarze C. E., Christmann M. et al. [Characteristics of university students using stimulants for cognitive enhancement: a pilot study]. Psychiatr Prax: 2012; 39 174 180
55. Dietz P., Striegel H., Franke A. G. et al. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy: 2013; 33 44 50
56. Deline S., Baggio S., Studer J. et al. Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland. Int J Environ Res Public Health: 2014; 11 3032 3045
57. Maier L. J., Liechti M. E., Herzig F. et al. To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One: 2013; 8 e77967
58. Ott R., Biller-Andorno N. Neuroenhancement among Swiss students - a comparison of users and non-users. Pharmacopsychiatry: 2014; 47 22 28
59. Burgard D. A., Fuller R., Becker B. et al. Potential trends in Attention Deficit Hyperactivity Disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ: 2013; 450-451 242 249
60. Franke A. G., Bagusat C., Dietz P. et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med: 2013; 11 102
61. Franke A. G., Bagusat C., McFarlane C. et al. The Use of Caffeinated Substances by Surgeons for Cognitive Enhancement. Ann Surg: 2014; 10.1097/SLA.0000000000000830
62. Hughes J. R., Oliveto A. H., Helzer J. E. et al. Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Am J Psychiatry: 1992; 149 33 40
63. Satel S. Is caffeine addictive? - a review of the literature. Am J Drug Alcohol Abuse: 2006; 32 493 502
64. Kaminer Y. Problematic use of energy drinks by adolescents. Child Adolesc Psychiatr Clin N Am: 2010; 19 643 650
65. Iversen L. Speed, Ecstasy, Ritalin. Amphetamine - Theorie und Praxis. Bern Verlag Hans Huber: 2009
66. Tossmann P., Boldt S., Tensil M. D. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res: 2001; 7 2 23
67. Gahr M., Freudenmann R. W., Hiemke C. et al. Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res: 2014; 215 252 254
68. Clemow D. B., Walker D. J. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med: 2014; 126 64 81
69. Stempel K. Rauschgiftlage. In: DHS Hrsg Jahrbuch Sucht 2014. 2014 Lengerich Pabst: 2012; 141 153
70. Fleckenstein A. E., Volz T. J., Riddle E. L. et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol: 2007; 47 681 698
71. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of drugs of abuse - the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci: 2009; 11 305 317
72. Srisurapanont M., Jarusuraisin N., Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev: 2001; 10.1002/14651858.CD003022: CD003022
73. Vocci F., Ling W. Medications development: successes and challenges. Pharmacol Ther: 2005; 108 94 108
74. Shoptaw S. J., Kao U., Heinzerling K. et al. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev: 2009; 10.1002/14651858.CD003021.pub2: CD003021
75. Ling W., Rawson R., Shoptaw S. et al. Management of methamphetamine abuse and dependence. Curr Psychiatry Rep: 2006; 8 345 354
76. Lingford-Hughes A. R., Welch S., Nutt D. J. et al. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol: 2004; 18 293 335
77. Shearer J., Wodak A., Mattick R. P. et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction: 2001; 96 1289 1296